Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, and Cancer Immunotherapy and Biomarkers.
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Non–Small Cell Lung Cancer, Version 4.2024
Mesothelioma: Pleural, Version 1.2024
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
Nerve Graft Supported Optic Fiber Growth
Travel to Attend Fifth International Conference on Vacuum Ultraviolet Radiation Physics, Montpellier, France, Sept 5-9, 1977
Restructuring the Undergraduate Learning Environment